The presence of a nonlinear association between RBD-IgG antibody titer and MMF concentration was assessed using a restricted cubic spline regression model with 3 knots using the R rms package (R Foundation for Statistical Computing, Vienna, Austria)

The presence of a nonlinear association between RBD-IgG antibody titer and MMF concentration was assessed using a restricted cubic spline regression model with 3 knots using the R rms package (R Foundation for Statistical Computing, Vienna, Austria). We identified increased B-cell counts after withdrawal from MMF (P< .01). The recovery of antibody responses was Ellagic acid seen in SOTs withdrawn from MMF. The trajectories of antibody responses were modified by MMF administration. Vaccines against SARS-CoV-2 have been found to be effective and safe in both clinical trials and real-world settings [1,2]. Antibody responses after mRNA SARS-CoV-2 vaccination are well established in the general population[3],[4],[5],[6],[7]. However, the previous pioneering works revealed blunted antibody responses in solid organ transplant recipients (SOTs) who need continuous immunosuppressive medications to prevent rejection of the transplanted organs[8],[9],[10],[11],[12],[13],[14]. There is a paucity of data in SOTs who use potent immunosuppressants because they have been specifically excluded from SARS-CoV-2 vaccine trials [1,2]. Data from recent observational studies has suggested that a substantial proportion of patients with solid organ transplant, particularly those undergoing immunosuppression with mycophenolate mofetil (MMF), show attenuated antibody response even after a second or third vaccination [8,10,12,15,16]. We have demonstrated marked attenuation of antibody titers among transplant recipients with MMF in a dose-dependent manner after second doses of a SARS-CoV-2 vaccine[10]. In addition, in a report of a case series, seroconversions were confirmed after withdrawal from MMF in vaccinated transplant recipients without a third vaccination[15]. Based on such results, the identification Alas2 of the trajectories of antibody responses in SOTs in association with MMF administration is essential to elucidate optimal countermeasures in this vulnerable population. Whether the mid-term immunogenicity of SARS-CoV-2 vaccine is maintained in SOTs remains unclear [17,18]. Hence, to fill the gap in the evidence for this vulnerable population, we conducted the present study to identify the trajectory of antibody titers after SARS-CoV-2 vaccination among SOTs with or without MMF or withdrawal from MMF. The SOTs have a normal immune system but potently inhibited T- and B-cell responses to prevent transplant rejection. We thus also explored the associations between antibody titers and trough MMF concentrations and B- and T-cell counts, together with CD4- and CD8-positive T-cell counts, in SOTs after the second dose of SARS-CoV-2 vaccine. == Materials and Methods == == Study Design and Population == A prospective, single-center observational cohort study including SOTs receiving immunosuppressive therapy from Matsunami General Hospital, Japan, was conducted between July 1, 2021 and April 30, 2022. We included all patients who received second doses of the BNT162b2 mRNA SARS-CoV-2 vaccine (Pfizer/BioNTech). Patients with a history of polymerase chain reactionconfirmed diagnosis of COVID-19 or positive SARS-CoV-2 anti-nucleocapsid antibodies before the second vaccination were excluded. The SOT enrollment was stratified into 3 categories: with MMF, without MMF, and withdrawn from MMF. SOTs in the withdrawal category were tapered from MMF utilizing a decremental timetable based on the discretion from the participating in physician. The dosage of various other immunosuppressants could possibly be transformed as dictated by scientific necessity. Drawback from MMF was attempted in the time between your second and initial measurements of antibody titers. Apart from 1 individual, weaning from MMF was effective. One patient demonstrated an elevated liver organ function Ellagic acid test through the withdrawal and therefore MMF was still left on the maintenance dosage because of problems about rejection. No graft failing was seen in all sufferers. The trajectory of antibody titer was examined using thickness plots, linear mixed-effects types of longitudinal evaluation, and non-linear regression using a sturdy Huber-White sandwich estimator. == Test Collection and Follow-Up Timetable == The Ellagic acid initial 2 doses received at least 3 weeks.